Cat. No. 3313
Chemical Name: 5,7-Bis(1,1-dimethylethyl)-3-hydrox
Biological ActivityPotent and selective GABAB receptor positive allosteric modulator that increases the potency and efficacy of GABA ( > 15-fold and > 149% respectively). Exhibits anxiolytic activity in vivo and is orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Koek et al (2013) Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse. J.Pharmacol.Exp.Ther. 344 553. PMID: 23275067.
Malherbe et al (2008) Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br.J.Pharmacol. 154 797. PMID: 18536733.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses rac BHFF from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: rac BHFF, supplier, Potent, selective, GABAB, positive, allosteric, modulators, Receptors, Tocris Bioscience, GABAB Receptor Modulator products
Find multiple products by catalog number
New Products in this Area
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.